Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology

J Chemother. 2012 Feb;24(1):18-25. doi: 10.1179/1120009X12Z.0000000005.

Abstract

Caspofungin and nikkomycin Z (NIK) efficacy alone and in combination were tested against seven Candida species showing or not showing paradoxical growth (PG) against caspofungin in time-kill test in RPMI-1640. Selected isolates against caspofungin and NIK were also tested in 50% serum. PG was always eliminated by NIK as well as by serum. In the serum, 1 and 16 μg/ml caspofungin yielded 0.14-4.0 and 0.34-4.0 log CFU decreases from the starting inocula for C. albicans, C. glabrata, C. tropicalis, and C. dubliniensis, respectively. CFU decrease (0.10-2.08 log) at 16 μg/ml, but not at lower caspofungin concentration was noted against C. parapsilosis, C. orthopsilosis, and C. metapsilosis. One C. parapsilosis isolate was not inhibited even by 16 μg/ml caspofungin. Caspofungin against C. albicans, C. glabrata, C. tropicalis, and C. dubliniensis maintained its activity in serum at even 1 μg/ml concentration. PG seems to an in vitro phenomenon, without clinical relevance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides / pharmacology*
  • Antifungal Agents / pharmacology*
  • Candida / classification
  • Candida / drug effects*
  • Candida / growth & development
  • Candidiasis / drug therapy*
  • Candidiasis / microbiology*
  • Caspofungin
  • Drug Therapy, Combination
  • Echinocandins / pharmacology*
  • Humans
  • Lipopeptides
  • Microbial Sensitivity Tests
  • Serum / metabolism*
  • Time Factors

Substances

  • Aminoglycosides
  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • nikkomycin
  • Caspofungin